文献速递腹部MR

避免使用对比增强序列不影响简化MaRIA评估非穿透性克罗恩病活动度的精确性

Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity.
PubMed 文献 · Eur Radiol · 2022-01-15

本研究为前瞻性研究的事后分析,纳入46例有内镜下溃疡且开始生物制剂治疗的克罗恩病患者,由两名盲法放射科医师分别仅用非增强序列(T2-sMaRIA)和联合增强序列(CE-sMaRIA)评分,结果显示两者与回结肠镜在溃疡愈合、治疗反应和缓解方面的一致性相似。

要点

  • 简化MaRIA可仅用非增强序列评估克罗恩病生物制剂治疗反应,与联合增强序列结果相当。
  • T2-sMaRIA与回结肠镜在溃疡愈合上的一致性kappa=0.70,CE-sMaRIA为kappa=0.74。
  • 避免静脉对比剂可缩短MRE检查时间、降低成本并提高安全性和接受度。

核心结论

  • 联合或不联合对比增强图像的sMaRIA均能准确按照回结肠镜确定的不同治疗终点对治疗反应进行分类。

研究设计与样本

  • 前瞻性研究的事后分析,纳入46例至少1个肠段存在内镜下溃疡并开始生物制剂治疗的克罗恩病患者,中位年龄36岁(IQR:28-47);两名盲法放射科医师分别于基线和治疗第46周,先仅用非增强序列评分(T2-sMaRIA),1个月后联合非增强和增强图像评分(CE-sMaRIA),以回结肠镜为参考标准。

诊断标准与关键数值

  • T2-sMaRIA与回结肠镜识别溃疡愈合的一致性kappa=0.70(0.5-0.9),CE-sMaRIA为kappa=0.74(0.55-0.93)。
  • T2-sMaRIA与回结肠镜识别治疗反应的一致性kappa=0.44(0.17-0.71),CE-sMaRIA为kappa=0.53(0.28-0.79)。
  • T2-sMaRIA与回结肠镜识别缓解的一致性kappa=0.43(0.17-0.69),CE-sMaRIA为kappa=0.48(0.22-0.73)。
  • CE-sMaRIA标准化效应量为0.63(0.41-0.85),P<0.001;T2-sMaRIA为0.58(0.36-0.80),P<0.001。

临床应用与阅片要点

  • sMaRIA使用四个二分变量成分,可无需对比增强序列进行评估,具有实用性和安全性优势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Patients with Crohn's disease (CD) require multiple assessments with magnetic resonance enterography (MRE) from a young age. Standard MRE protocols for CD include contrast-enhanced sequences. Gadolinium deposits in brain tissue suggest avoiding gadolinium could benefit patients with CD. This study aimed to compare the accuracy of the simplified Magnetic Resonance Index of Activity (sMaRIA) calculated with and without contrast-enhanced sequences in determining the response to biologic drugs in patients with CD.

METHODS: This post hoc analysis of a prospective study included patients with CD with endoscopic ulceration in ≥ 1 intestinal segment starting biologic drug therapy. Two blinded radiologists used the sMaRIA to score images obtained at baseline and week 46 of treatment first using only unenhanced sequences (T2-sMaRIA) and 1 month later using both unenhanced and enhanced images (CE-sMaRIA). We calculated the rates of agreement between T2-sMaRIA, CE-sMaRIA, and ileocolonoscopy for different conceptualizations of therapeutic response.

RESULTS: A total of 46 patients (median age, 36 years [IQR: 28-47]) were included. Agreement with ileocolonoscopy was similar for CE-sMaRIA and T2-sMaRIA in identifying ulcer healing (kappa = 0.74 [0.55-0.93] and 0.70 [0.5-0.9], respectively), treatment response (kappa = 0.53 [0.28-0.79] and 0.44 [0.17 - 0.71]), and remission (kappa = 0.48 [0.22-0.73] and 0.43 [0.17-0.69]). The standardized effect size was moderate for both CE-sMaRIA = 0.63 [0.41-0.85] p < 0.001 and T2-sMaRIA = 0.58 [0.36-0.80] p < 0.001.

CONCLUSIONS: sMaRIA with and without contrast-enhanced images accurately classified the response according to different therapeutic endpoints determined by ileocolonoscopy.

KEY POINTS: • The simplified Magnetic Resonance Index of Activity is accurate for the assessment of Crohn's disease activity, severity, and therapeutic response, using four dichotomic components that can be evaluated without the need of using contrast-enhanced sequences, representing a practical and safety advantage, but concerns have been expressed as to whether the lack of contrast sequences may compromise precision. • The simplified Magnetic Resonance Index of Activity can assess the response to biologic therapy in patients with Crohn's disease without the need for intravenous contrast agents obtaining comparable results without and with contrast-enhanced sequences. • Avoiding intravenous contrast agents could reduce the duration of the MRE examination and its cost and would increase the acceptance and safety of MRE in clinical research in patients with Crohn's disease.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Fernàndez-Clotet, Sapena, Capozzi, et al. Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity. Eur Radiol. 2022. PMID: 35031844. doi:10.1007/s00330-021-08392-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。